Emtricitabine

證據等級: L5

預測適應症: 3 個

Emtricitabine: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV-1 infection. The TxGNN model predicts it may be effective for Feline Acquired Immunodeficiency Syndrome (FIV), with 4 clinical trials and 1 publication currently attached as supporting evidence — though only the publication directly studies the predicted (feline) indication; the trials are human HIV-1 studies of the drug's original use.

⚠️ Important caveat: The top-ranked predicted indication is a veterinary condition (feline AIDS caused by Feline Immunodeficiency Virus, FIV — a lentivirus related to but distinct from HIV). This likely reflects FIV/HIV similarity in the underlying knowledge graph rather than a human-indication signal. Rank 2 ("simian immunodeficiency virus infection") is also a non-human condition. Both should be interpreted as mechanistic/model artifacts, not ready-to-use human repurposing candidates.

Quick Overview

Item	Content
Original Indication	Not provided in structured data; based on established pharmacology, HIV-1 infection (antiretroviral therapy, typically combined with tenofovir)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (FIV) — veterinary condition
TxGNN Prediction Score	99.92%
Evidence Level	L4 (single preclinical/animal PK-outcomes study directly on-target; attached clinical trials are for the original human HIV-1 indication, not FIV)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, emtricitabine is a cytidine-analog NRTI that inhibits HIV-1 reverse transcriptase, and it is a core component of first-line combination antiretroviral therapy (cART) for human HIV-1 infection.

Mechanistically, the predicted link to FIV is plausible: FIV is a lentivirus closely related to HIV, and NRTIs targeting reverse transcriptase can theoretically inhibit FIV replication in the same way they inhibit HIV. This is supported by the one directly relevant publication in the evidence pack, which evaluated emtricitabine as part of a cART regimen in FIV-infected domestic cats.

However, the four clinical trials listed under this "indication" are all human HIV-1 treatment-naive trials evaluating emtricitabine/tenofovir-containing regimens against comparator ART (dolutegravir, raltegravir, darunavir combinations) — they support emtricitabine's established human HIV-1 use, not the FIV indication itself. This distinction should be made explicit to any reviewer relying on this report, since counting them as "FIV evidence" would overstate the evidence base.

Clinical Trial Evidence

Note: the trials below evaluate emtricitabine in human HIV-1 infection (its established use), not the predicted feline indication. They are included as they appear in the evidence pack for indication rank 1.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01263015	Phase 3	Completed	844	Dolutegravir + abacavir/lamivudine vs. Atripla (efavirenz/emtricitabine/tenofovir) in ART-naive HIV-1 adults, 96-week non-inferiority
NCT01227824	Phase 3	Completed	828	Dolutegravir vs. raltegravir, both with fixed-dose dual NRTI (including emtricitabine/tenofovir), in ART-naive HIV-1 adults
NCT02770508	Phase 4	Completed	145	Boosted darunavir + lamivudine vs. + emtricitabine/tenofovir or lamivudine/tenofovir in ART-naive HIV-1 patients
NCT00951015	Phase 2	Completed	208	Dose-finding for dolutegravir with abacavir/lamivudine or tenofovir/emtricitabine in ART-naive HIV-1 adults

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37112803	2023	Preclinical (animal)	Viruses	Combination ART (dolutegravir, tenofovir, emtricitabine) evaluated for pharmacokinetics and clinical/immunophenotypic outcomes in FIV-infected domestic cats — the only study directly on the predicted indication

Norway Market Information

Emtricitabine currently holds no marketing authorization in Norway (0 licenses on record); no product/dosage-form data is available for this market.

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug interaction data were available in this evidence pack (DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication is a veterinary condition (feline AIDS/FIV), and the attached clinical trial evidence supports only the drug's existing human HIV-1 use rather than the new indication itself — leaving just one preclinical animal study as direct evidence. Combined with the absence of MOA, safety, and Norway market data, the evidence base is not sufficient to support a repurposing recommendation as-is.

To proceed, the following is needed:

Clarify whether the TxGNN prediction is intended as a human-relevant signal (e.g., via FIV/HIV mechanistic homology) or should be excluded as a cross-species knowledge-graph artifact
Obtain emtricitabine mechanism of action (MOA) data from DrugBank (DG002)
Obtain formal product label warnings/contraindications/DDI data — currently a blocking gap for safety review (DG001)
If pursuing a human repurposing angle, re-run evidence review against human-relevant indications (e.g., other lentivirus/retrovirus-related conditions) rather than the FIV-labeled node
Confirm regulatory pathway options given the drug is not currently marketed in Norway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.